Cargando…
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial
Autores principales: | Stalder, Grégoire, Suffiotti, Madeleine, Segot, Amandine, Noto, Alessandra, Pantaleo, Giuseppe, Spertini, Olivier, Obeid, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827158/ https://www.ncbi.nlm.nih.gov/pubmed/36073517 http://dx.doi.org/10.3324/haematol.2022.281221 |
Ejemplares similares
-
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023) -
Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
por: Wei, Liqiang, et al.
Publicado: (2020) -
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021) -
The role of etoposide in the treatment of adult patients with hemophagocytic lymphohistiocytosis
por: Zondag, Timo C. E., et al.
Publicado: (2023) -
Etoposide in patients with rheuma-associated hemophagocytic lymphohistiocytosis / macrophage activation syndrome
por: Henter, Jan-Inge, et al.
Publicado: (2011)